Acasti Gets New Composition & Use Patents

Acasti Pharma, which develops CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, said pre-market Monday that it obtained additional patents from the Taiwanese and Australian patent offices, further expanding the intellectual property position of CaPre. The granted patents are valid until 2030 and relate to concentrated therapeutic krill oil-based phospholipid omega-3 compositions covering methods for treating or preventing disorders associated with cardiovascular diseases.

These patents add to Acasti’s growing portfolio of issued patents in the United States, China, Mexico, Saudi Arabia, Panama, and South Africa. Patent applications with similar claim sets are being pursued in many other jurisdictions worldwide.